Methods
We evaluated whether human anti-VCAM-1 mAb binds to human ormouse VCAM-1. Leukocyte adhesion inhibition assay was performed toevaluate the in vitro blocking activity of human anti-VCAM-1 mAb. OVAsensitized BALB/c mice were treated with human anti-VCAM-1 mAb orisotype control Ab before intranasal OVA challenge. We evaluated airwayhyperresponsiveness (AHR) and cell counts in bronchoalveolar lavage (BAL)fluid, measured inflammatory cytokines, and examined histopathologicalfeatures, including VCAM-1 immunohistochemistry.
Results
The human anti-VCAM-1 mAb bound to human and mouse VCAM-1molecules and inhibited adhesion of human leukocytes in vitro. AHR andinflammatory cell counts in BAL fluid were reduced in mice treated withhuman anti-VCAM-1 mAb as compared to a control Ab. The levels ofinterleukin (IL)-5 and IL-13, and transforming growth factor-β in lung tissuewere decreased in treated mice. Human anti-VCAM-1 mAb reduced goblet cellhyperplasia and peribronchial fibrosis. In vivo VCAM-1 expression decreasedin treated group.
Human anti-VCAM-1 mAb can attenuate allergic inflammationand pathophysiological features of asthma in OVA induced murine asthmamodel. This data suggested that human anti-VCAM-1 mAb could be an additionalantiasthma therapeutic medicine.
